The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Open accessAbstract
Assessment of Alzheimer's disease (AD)-related neurofibrillary pathology requires a procedure that permits a sufficient differentiation between initial, intermediate, and late stages. The gradual deposition of a hyperphosphorylated tau protein within select neuronal types in specific nuclei or areas is central to the disease process. The staging of AD-related neurofibrillary pathology originally described in 1991 was performed on unconventionally thick sections (100 mum) using a modern silver technique and reflected the progress of the disease process based chiefly on the topographic expansion of the lesions. To better meet the demands of routine laboratories this procedure is revised here by adapting tissue selection and processing to the needs of paraffin-embedded sections (5-15 mum) and by introducing a robust immunoreaction (AT8) for hyperphosphorylated tau protein that can be processed on an automated basis. It is anticipated that this revised methodological protocol will enable a more uniform application of the staging procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulation of Aβ plaques and NFTs follows distinct regional progressions across brain regions as AD advances.”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with the stereotypical hierarchical accumulation of NFTs along neural networks20,21”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They were categorized into the stage C of amyloid deposition and the stage VI of neurofibrillary degeneration, following the Braak's staging (13).”
From Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease (2017) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“by definition, the primary visual cortex (V1 region) bears NFTs only in Braak NFT stage VI20,21”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“we rank ordered the five brain regions based on their known vulnerability to neurofibrillary degeneration20,21 (that is, EC > ITG > PFC > V2 > V1)”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“the distinguishing feature between Braak NFT stages V and VI is not just the presence of NFTs in the primary visual (V1), motor and sensory cortical areas, but more severe neurofibrillary degeneration21 and atrophy throughout the cortical mantle51”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
In the citing paper
“A further pathological determinant is loss of neurons, which occurs predominantly in the cortex, the hippocampal formation, and the nucleus basalis of Meynert [2, 3, 18, 22, 25].”
From Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice (2008) · cites this paper as [2]
In the citing paper
“We consider it to be an important clue that most brains from elderly human subjects show abnormalities that fall somewhere along particular continua of pathologic severity (60, 96-100).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Self-citationFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Self-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
(1964) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb115841.x · Cited by 1,411
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.
Delacourte, A., David, J. P., Sergeant, N., Buée, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-Bianco, C., Pasquier, F., Lebert, F., et al. (1999) · Neurology · doi:10.1212/wnl.52.6.1158 · Cited by 828
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Braak, F., Braak, H., & Mandelkow, E. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 769
Self-citation
Research works printed but not linked: 7
- Alzheimer A (1906) Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurolog Centralbl 23:1129–1136
- Bielschowsky M (1902) Die Silberimprägnation der Axenzylinder. Neurol Centralb 13:579–584
- Bielschowsky M (1903) Die Silberimprägnation der Neurofibrillen. Neurol Centralb 21:997–1006
- Bielschowsky M (1904) Die Silberimprägnation der Neurofibrillen. Einige Bemerkungen zu der von mir angegebenen Methode und den von ihr gelieferten Bildern. J Psychol Neurol 3:169–189
- Bielschowsky M (1905) Die Darstellung der Axenzylinder peripherischer Nervenfasern und der Axenzylinder zentraler markhaltiger Nervenfasern. Ein Nachtrag zu der von mir angegebenen Imprägnationsmethode der Neurofibrillen. J Psychol Neurol 4:228–231
- Bielschowsky M (1909) Eine Modifikation meines Silberimprägnations-verfahrens zur Darstellung der Neurofibrillen. J Psychol Neurol 12:135–137
- Duyckaerts C, He Y, Seilhean D, Delaère P, Piette F, Braak H, Hauw JJ (1994) Diagnosis and staging of Alzheimer’s disease in a prospective study involving aged individuals. Neurobiol Aging 15(Suppl 1):140–141
Cited by
Sorted by citations
Items 701–800 of 1,028
Muñoz‐Ruiz, M. Á., Hartikainen, P. H., Koikkalainen, J. R., Wolz, R., Julkunen, V., Niskanen, E. I., Herukka, S., Kivipelto, M., Vanninen, R. L., Rueckert, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052531 · Cited by 64
Capillary CAA and perivascular Aβ-deposition: Two distinct features of Alzheimer's disease pathology
Attems, J., Yamaguchi, H., Saido, T. C., & Thal, D. R. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.030 · Cited by 63
Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology
Shelkovnikova, T. A., Kulikova, A. A., Tsvetkov, P. O., Peters, O. M., Бачурин, С. О., Buchman, V. L., & Ninkina, N. N. (2012) · Molecular Biology · doi:10.1134/s0026893312020161 · Cited by 63
Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy
Ishiki, A., Harada, R., Kai, H., Sato, N., Totsune, T., Tomita, N., Watanuki, S., Hiraoka, K., Ishikawa, Y., Funaki, Y., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0556-7 · Cited by 63
Postmortem T 2 * - Weighted MRI Imaging of Cortical Iron Reflects Severity of Alzheimer’s Disease
Bulk, M., Kenkhuis, B., van der Graaf, L. M., Goeman, J. J., Natté, R., & van der Weerd, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180317 · Cited by 63
Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis
Walton, C. C., Begelman, D. V., Nguyen, W., & Andersen, J. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00129 · Cited by 62
Mitochondrial complex I deficiency stratifies idiopathic Parkinson’s disease
Flønes, I. H., Toker, L., Sandnes, D. A., Castelli, M., Mostafavi, S., Lura, N. G., Shadad, O., Fernández‐Vizarra, E., Painous, C., Pérez‐Soriano, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47867-4 · Cited by 67
Correlations between cortical and subcortical tau pathology
Attems, J., Thomas, A. J., & Jellinger, K. A. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01244.x · Cited by 65
Cofilin Rods and Aggregates Concur with Tau Pathology and the Development of Alzheimer's Disease
Rahman, T., Davies, D. S., Tannenberg, R. K., Fok, S., Shepherd, C., Dodd, P. R., Cullen, K. M., & Goldsbury, C. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140393 · Cited by 63
Kälin, A. M., Park, M. T. M., Chakravarty, M. M., Lerch, J. P., Michels, L., Schroeder, C., Broicher, S. D., Kollias, S., Nitsch, R. M., Gietl, A. F., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00038 · Cited by 64
Topographic staging of tau positron emission tomography images
Schwarz, A. J., Shcherbinin, S., Slieker, L. J., Risacher, S. L., Charil, A., Irizarry, M. C., Fleisher, A., Southekal, S. S., Joshi, A. D., Devous, M. D., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.006 · Cited by 63
Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease
Egroo, M. V., Narbutas, J., Chylinski, D., González, P. V., Maquet, P., Salmon, É., Bastin, C., Collette, F., & Vandewalle, G. (2019) · SLEEP · doi:10.1093/sleep/zsz017 · Cited by 66
Parkinsonism and Related Disorders
Slow, E., & Lang, A. E. (2019) · DeckerMed Transitional Year Weekly Curriculum™ · doi:10.2310/tywc.1178 · Cited by 62
Russell, C. L., Mitra, V., Hansson, K., Blennow, K., Gobom, J., Zetterberg, H., Hiltunen, M., Ward, M., & Pike, I. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160633 · Cited by 52
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Microglial Activation and Connectivity in Alzheimer Disease and Aging
Rauchmann, B., Brendel, M., Franzmeier, N., Trappmann, L., Zaganjori, M., Ersoezlue, E., Morenas‐Rodriguez, E., Guersel, S., Burow, L., Kurz, C., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26465 · Cited by 61
“Increasing evidence indicates that the spread of tau tangles in the neocortex is accompanied by microglial activation,(13,20) with both types of pathologies seemingly following a Braak-stagelike distribution pattern along an activated network of microglia, suggesting that Aβ and microglia together initiate tau spreadi…”
Higashi, S., Moore, D. J., Minegishi, M., Kasanuki, K., Fujishiro, H., Kabuta, T., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., et al. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318211c86a · Cited by 62
Takeuchi, R., Tada, M., Shiga, A., Toyoshima, Y., Konno, T., Sato, T., Nozaki, H., Kato, T., Horie, M., Shimizu, H., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0335-2 · Cited by 66
Cell type-specific changes identified by single-cell transcriptomics in Alzheimer’s disease
Luquez, T., Gaur, P., Kosater, I. M., Lam, M., Lee, D. I., Mares, J. A., Paryani, F., Yadav, A., & Menon, V. (2022) · Genome Medicine · doi:10.1186/s13073-022-01136-5 · Cited by 64
Qiu, Y., Shen, X., Ravid, O., Atrakchi, D., Rand, D., Wight, A. E., Kim, H.-J., Zaltsman, S. L., Cooper, I., Beeri, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218915120 · Cited by 62
Cell-type-directed network-correcting combination therapy for Alzheimer’s disease
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.035 · Cited by 66
α-Synuclein pathology in the neostriatum in Parkinson’s disease
Mori, F., Tanji, K., Zhang, H., Kakita, A., Takahashi, H., & Wakabayashi, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0316-4 · Cited by 61
The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain
McDonald, J. M., Cairns, N. J., Taylor‐Reinwald, L., Holtzman, D. M., & Walsh, D. M. (2012) · Brain Research · doi:10.1016/j.brainres.2012.02.041 · Cited by 61
Satoh, J. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10r11fm · Cited by 61
Ross, J. A., Gliebus, G. P., & Bockstaele, E. J. V. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.08.004 · Cited by 63
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 62
Fractional Anisotropy changes in Parahippocampal Cingulum due to Alzheimer’s Disease
da Rocha, J. L. D., Bramati, I. E., Coutinho, G., Tovar-Moll, F. F., & Sitaram, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59327-2 · Cited by 61
Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60
Ferrer, I., Andrés‐Benito, P., Ausín, K., Pamplona, R., del Río, J. A., Fernández‐Irigoyen, J., & Santamaría, E. (2021) · Brain Pathology · doi:10.1111/bpa.12996 · Cited by 61
TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT
Ling, H., Kara, E., Bandopadhyay, R., Hardy, J., Holton, J. L., Xiromerisiou, G., Lees, A. J., Houlden, H., & Révész, T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.011 · Cited by 60
on behalf of the MRC Cognitive Function and Ageing Neuropathology Study Group, Wharton, S. B., Minett, T., Drew, D., Forster, G., Matthews, F. E., Brayne, C., & Ince, P. G. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0275-x · Cited by 61
Lachén‐Montes, M., González-Morales, A., de Morentin, X. M., Pérez‐Valderrama, E., Ausín, K., Zelaya, M. V., Serna, A., Aso, E., Ferrer, I., Fernández‐Irigoyen, J., et al. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.07.032 · Cited by 61
Receptors for pro‐resolving mediators are increased in Alzheimer's disease brain
Emre, C., Hjorth, E., Bharani, K., Carroll, S., Granholm, A., & Schultzberg, M. (2020) · Brain Pathology · doi:10.1111/bpa.12812 · Cited by 60
Selvackadunco, S., Langford, K., Shah, Z., Hurley, S. M., Bódi, I., King, A., Aarsland, D., Troakes, C., & Al‐Sarraj, S. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-018-01967-w · Cited by 63
The temporal onset of the core features in dementia with Lewy bodies
Choudhury, P., Graff‐Radford, J., Aakre, J. A., Wurtz, L. I., Knopman, D. S., Graff‐Radford, N. R., Kantarci, K., Forsberg, L. K., Fields, J. A., Pedraza, O., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12411 · Cited by 59
Louis, E. D., Martuscello, R. T., Gionco, J. T., Hartstone, W. G., Musacchio, J. B., Portenti, M., McCreary, M., Kuo, S., Vonsattel, J., & Faust, P. L. (2023) · Acta Neuropathologica · doi:10.1007/s00401-022-02535-z · Cited by 59
Neuronal identity defines α-synuclein and tau toxicity
Praschberger, R., Kuenen, S., Schoovaerts, N., Kaempf, N., Singh, J., Janssens, J., Swerts, J., Nachman, E., Calatayud, C., Aerts, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.02.033 · Cited by 66
Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides
Oberstein, T. J., Spitzer, P., Klafki, H., Linning, P., Neff, F., Knölker, H., Lewczuk, P., Wiltfang, J., Kornhuber, J., & Maler, J. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.031 · Cited by 64
Synapto-Protective Drugs Evaluation in Reconstructed Neuronal Network
Deleglise, B., Lassus, B., Soubeyre, V., Alleaume‐Butaux, A., Hjorth, J. J. J., Vignes, M., Schneider, B., Brugg, B., Viovy, J., & Peyrin, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071103 · Cited by 70
Gierga, K., Schelhaas, H. J., Brunt, E. R. P., Seidel, K., Scherzed, W., Egensperger, R., de Vos, R. A. I., den Dunnen, W. F. A., Ippel, P. F., Petrasch‐Parwez, E., et al. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01015.x · Cited by 59
Gandhi, N. S., Landrieu, I., Byrne, C., Kukić, P., Amniai, L., Cantrelle, F., Wieruszeski, J., Mancera, R. L., Jacquot, Y., & Lippens, G. M. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501898 · Cited by 59
Okuda, M., Fujita, Y., Hijikuro, I., Wada, M., Uemura, T., Kobayashi, Y., Waku, T., Tanaka, N., Nishimoto, T., Izumi, Y., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161017 · Cited by 59
Despres, C., Di, J., Cantrelle, F., Li, Z., Huvent, I., Chambraud, B., Zhao, J., Chen, J., Chen, S., Lippens, G. M., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00325 · Cited by 62
Single particle analysis of tau oligomer formation induced by metal ions and organic solvents
Bader, B., Nübling, G., Mehle, A., Nobile, S., Kretzschmar, H. A., & Giese, A. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.135 · Cited by 58
Self-citationTau-related white-matter alterations along spatially selective pathways
Wen, Q., Risacher, S. L., Xie, L., Li, J., Harezlak, J., Farlow, M. R., Unverzagt, F. W., Gao, S., Apostolova, L. G., Saykin, A. J., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117560 · Cited by 60
Koscik, R. L., Hermann, B. P., Allison, S. L., Clark, L. R., Jonaitis, E. M., Mueller, K. D., Betthauser, T. J., Christian, B. T., Du, L., Okonkwo, O. C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.688478 · Cited by 58
Liu, P., Yang, Q., Yu, N., Cao, Y., Wang, X., Wang, Z., Qiu, W.-Y., & Ma, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210461 · Cited by 59
Schoor, E. V., Ospitalieri, S., Moonen, S., Tomé, S. O., Ronisz, A., Ok, O., Weishaupt, J. H., Ludolph, A. C., Damme, P. V., Bosch, L. V. D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02466-9 · Cited by 64
Relationship of serum beta‐synuclein with blood biomarkers and brain atrophy
Oeckl, P., Anderl‐Straub, S., Danek, A., Diehl‐Schmid, J., Fassbender, K. C., Fließbach, K., Halbgebauer, S., Huppertz, H., Jahn, H., Kassubek, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12790 · Cited by 61
Ruíz‐Barrio, I., Miki, Y., Jaunmuktane, Z., Warner, T. T., & Pablo‐Fernández, E. D. (2022) · Neurology · doi:10.1212/wnl.0000000000201659 · Cited by 58
Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity
Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 58
Minimal change multiple system atrophy: An aggressive variant?
Ling, H., Asi, Y. T., Petrovic, I. N., Ahmed, Z., Kukkle, P. L., Hazrati, L., Nishizawa, M., Ozawa, T., Lang, A. E., Lees, A. J., et al. (2015) · Movement Disorders · doi:10.1002/mds.26220 · Cited by 58
Curcumin Labeling of Neuronal Fibrillar Tau Inclusions in Human Brain Samples
Mohorko, N., Repovš, G., Popović, M., Kovács, G. G., & Bresjanac, M. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181d709eb · Cited by 60
Jellinger, K. A., & Attems, J. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000327360 · Cited by 58
Wharton, S. B., O'Callaghan, J. P., Savva, G. M., Nicoll, J. A. R., Matthews, F. E., Simpson, J. E., Forster, G., Shaw, P. J., Brayne, C., & Ince, P. G. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000217729 · Cited by 60
Demyelination in Mild Cognitive Impairment Suggests Progression Path to Alzheimer’s Disease
Carmeli, C., Donati, A., Antille, V., Viceic, D., Ghika, J. A., von Gunten, A., Clarke, S., Meuli, R. A., Frackowiak, R. S. J., & Knyazeva, M. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072759 · Cited by 57
Lau, H. H. C., Ingelsson, M., & Watts, J. C. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02201-2 · Cited by 57
Structural Basis of Tau Interaction With BIN1 and Regulation by Tau Phosphorylation
Lasorsa, A., Malki, I., Cantrelle, F.-X., Merzougui, H., Boll, E., Lambert, J.-C., & Landrieu, I. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00421 · Cited by 58
Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U
Lee, E. B., Russ, J., Jung, H., Elman, L. B., Chahine, L. M., Kremens, D. E., Miller, B. L., Coslett, H. B., Trojanowski, J. Q., Deerlin, V. M. V., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-9 · Cited by 58
Furcila, D., Domínguez-Álvaro, M., DeFelipe, J., & Alonso‐Nanclares, L. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00099 · Cited by 59
Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks
Schumacher, J., Gunter, J. L., Przybelski, S. A., Jones, D. T., Graff‐Radford, J., Savica, R., Schwarz, C. G., Senjem, M. L., Jack, C. R., Lowe, V. J., et al. (2021) · Brain · doi:10.1093/brain/awab218 · Cited by 57
González-Rodríguez, M., Villar‐Conde, S., Astillero‐Lopez, V., Villanueva‐Anguita, P., Úbeda‐Bañón, I., Flores‐Cuadrado, A., Martínez-Marcos, A., & Saiz‐Sánchez, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010165 · Cited by 58
Vontell, R. T., de Rivero Vaccari, J. P., Sun, X., Gultekin, S. H., Bramlett, H. M., Dietrich, W. D., & Keane, R. W. (2023) · Brain Pathology · doi:10.1111/bpa.13142 · Cited by 57
Franklin, E. E., Perrin, R. J., Vincent, B. D., Baxter, M., Morris, J. C., Cairns, N. J., & Initiative, A. D. N. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.010 · Cited by 57
Geser, F., Prvulovic, D., O’Dwyer, L., Hardiman, O. M., Bede, P., Bokde, A. L. W., Trojanowski, J. Q., & Hampel, H. J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.011 · Cited by 58
Ashby, E. L., Miners, J. S., Kehoe, P. G., & Love, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150831 · Cited by 60
Cox, K. K., Combs, B., Abdelmesih, B., Morfini, G. A., Brady, S. T., & Kanaan, N. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.015 · Cited by 62
Saint‐Aubert, L., Almkvist, O., Chiotis, K., Almeida, R., Wall, A. E., & Nordberg, A. K. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0204-z · Cited by 58
Lemoine, L., Saint‐Aubert, L., Nennesmo, I., Gillberg, P., & Nordberg, A. K. (2017) · Scientific Reports · doi:10.1038/srep45496 · Cited by 55
Owen, J. E., Benediktsdóttir, B., Cook, E., Ólafsson, Í., Gíslason, Þ., & Robinson, S. R. (2020) · SLEEP · doi:10.1093/sleep/zsaa195 · Cited by 59
Sleep–wake changes and cognition in neurodegenerative disease
Naismith, S. L., Lewis, S. J. G., & Rogers, N. L. (2011) · Progress in brain research · doi:10.1016/b978-0-444-53817-8.00002-5 · Cited by 59
Tse, K., Cheng, A., Ma, F., & Herrup, K. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.010 · Cited by 56
Simpson, J. E., Ince, P. G., Matthews, F. E., Shaw, P. J., Heath, P. R., Brayne, C., Garwood, C., Higginbottom, A., Wharton, S. B., & MRC Cognitive Function and Ageing Neuropathology Study Group (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12202 · Cited by 56
Martiskainen, H., Viswanathan, J., Nykänen, N.-P., Kurki, M., Helisalmi, S., Natunen, T., Sarajärvi, T., Kurkinen, K. M. A., Pursiheimo, J.-P., Rauramaa, T., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.003 · Cited by 70
Self-citationProteomic Atlas of the Human Brain in Alzheimer’s Disease
McKetney, J., Runde, R. M., Hebert, A. S., Salamat, S. M., Roy, S., & Coon, J. J. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00004 · Cited by 54
BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease
Campo, M. D., Hoozemans, J. J. M., Dekkers, L.-L., Rozemüller, A. J. M., Korth, C., Müller‐Schiffmann, A., Scheltens, P., Blankenstein, M. A., Jiménez, C. R., Veerhuis, R., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.007 · Cited by 54
Hyposmia in progressive supranuclear palsy
Silveira‐Moriyama, L., Hughes, G. R. V., Church, A., Ayling, H., Williams, D. R., Petrie, A., Holton, J. L., Révész, T., Kingsbury, A. E., Morris, H. R., et al. (2010) · Movement Disorders · doi:10.1002/mds.22688 · Cited by 57
Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology
Monsell, S. E., Mock, C., Roe, C. M., Ghoshal, N., Morris, J. C., Cairns, N. J., & Kukull, W. A. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d7a1 · Cited by 57
Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies
Garcia‐Esparcia, P., Lucena, D. D., Ainciburu, M., Torrejón-Escribano, B., Carmona, M., Llorens, F., & Ferrer, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00122 · Cited by 56
de Florès, R., Berron, D., Ding, S., Ittyerah, R., Pluta, J. B., Xie, L., Adler, D. H., Robinson, J. L., Schuck, T., Trojanowski, J. Q., et al. (2019) · Hippocampus · doi:10.1002/hipo.23172 · Cited by 53
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Lantero‐Rodriguez, J., Snellman, A., Benedet, A. L., Milà‐Alomà, M., Camporesi, E., Montoliu‐Gaya, L., Ashton, N. J., Vrillon, A., Karikari, T. K., Gispert, J. D., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202115098 · Cited by 59
Structural Neuroimaging in the Detection and Prognosis of Pre-Clinical and Early AD
Fennema‐Notestine, C., McEvoy, L. K., Hagler, D. J., Jacobson, M. W., Dale, A. M., & Initiative, T. A. D. N. (2009) · Behavioural Neurology · doi:10.1155/2009/698156 · Cited by 58
Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease
Satoh, J.-I., Kino, Y., Yanaizu, M., Tosaki, Y., Sakai, K., Ishida, T., & Saito, Y. (2017) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2017.01073 · Cited by 55
Bastard, N. L., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J., & Engelborghs, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121246 · Cited by 55
Liu, M., Dexheimer, T. S., Sui, D., Hovde, S., Deng, X., Kwok, R. P. S., Bochar, D. A., & Kuo, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-73680-2 · Cited by 59
Colony stimulating factors in the nervous system
Chiţu, V., Biundo, F., & Stanley, E. R. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101511 · Cited by 57
Caspase‐6 as a novel early target in the treatment of Alzheimer's disease
LeBlanc, A. C. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12250 · Cited by 56
El‐Obeid, A., Laurell, K., Cesarini, K. G., & Alafuzoff, I. I. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000191 · Cited by 56
Self-citationElucidating Tau function and dysfunction in the era of cryo-EM
Lippens, G. M., & Gigant, B. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.008031 · Cited by 56
Kocagöncü, E., Quinn, A. J., Firouzian, A., Cooper, E., Greve, A., Gunn, R. N., Green, G. G. R., Woolrich, M. W., Henson, R. N., Lovestone, S., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.009 · Cited by 55
Esteves, A. R., & Cardoso, S. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-70174-z · Cited by 55
Iaccarino, L., Joie, R. L., Edwards, L., Strom, A., Schonhaut, D. R., Ossenkoppele, R., Pham, J. Q., Mellinger, T. J., Janabi, M., Baker, S. L., et al. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa184 · Cited by 56
Long-term effects of amyloid-beta deposits in human iPSC-derived astrocytes
Konstantinidis, E., Dakhel, A., Beretta, C., & Erlandsson, A. (2023) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2023.103839 · Cited by 56
Mundada, N. S., Rojas, J. C., VandeVrede, L. A., Thijssen, E. H., Iaccarino, L., Okoye, O., Shankar, R. P., Soleimani‐Meigooni, D. N., Lago, A. L., Miller, B. L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01302-w · Cited by 54
Unfolded protein response is activated in L ewy body dementias
Baek, J., Whitfield, D., Howlett, D. C., Francis, P. T., Bereczki, E., Ballard, C. G., Hortobágyi, T., Attems, J., & Aarsland, D. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12260 · Cited by 55
Kalaitzakis, M. E., Pearce, R. K. B., & Gentleman, S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.05.083 · Cited by 54
Amyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies
Slaets, S., Bastard, N. L., Theuns, J., Sleegers, K., Verstraeten, A., Leenheir, E. D., Luyckx, J., Martin, J., Broeckhoven, C. V., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122176 · Cited by 54
Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice
Li, X., Wang, Z., Tan, L., Wang, Y., Lu, C., Chen, R., Zhang, S., Gao, Y., Liu, Y., Yin, Y., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.010 · Cited by 53
Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG)
Kovács, G. G., Xie, S. X., Lee, E. B., Robinson, J. L., Caswell, C., Irwin, D. J., Toledo, J. B., Johnson, V. E., Smith, D. H., Alafuzoff, I. I., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx041 · Cited by 54
Self-citationFathy, Y. Y., Jonker, A. J., Oudejans, E., de Jong, F. J. J., van Dam, A., Rozemüller, A. J. M., & van de Berg, W. D. J. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12501 · Cited by 54
Metadata
- Authors
- Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K.
- Affiliations
- Goethe University Frankfurt (DE)
- Kuopio University Hospital (FI)
- Institut für Neuropathologie (DE)
- Corresponding author
- Braak, Heiko
- Venue
- Acta Neuropathologica
- Published
- 2006-08-12
- Volume
- 112
- Issue
- 4
- Pages
- 389-404
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC3906709
- OpenAlex
- W2093650784
- Cited by
- 3,172
- References
- 101
- Citations by year
- 2026: 218 · 2025: 259 · 2024: 334 · 2023: 254 · 2022: 251 · 2021: 261 · 2020: 228 · 2019: 205 · 2018: 157 · 2017: 135 · 2016: 140 · 2015: 118 · 2014: 134 · 2013: 95 · 2012: 77
- FWCI
- 34.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission (LSHM-CT-2004-503039)
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary pathology, disease staging, AT8 antibody, immunocytochemistry, paraffin sections, silver staining
- MeSH terms
- Alzheimer Disease, Humans, Immunohistochemistry, Amyloid beta-Peptides, Paraffin Embedding, Tissue Fixation, Neurofibrillary Tangles, tau Proteins, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
